The future role of vaccination in prevention of Neisseria gonorrhoeae
Bing Wang A B * , Kate L. Seib C and Helen Marshall A BA
B
C
Dr Bing Wang completed a PhD at The University of Adelaide in 2019. She received a MPhil degree in 2014 from The University of Adelaide and a bachelor’s degree in medicine from the Capital Medical University (Beijing, China). She has been working with her supervisor, Prof. Helen Marshall, on projects that require complex statistical analyses and have a health economic focus. She worked in the clinical research area for more than 10 years in GlaxoSmithKline (Beijing, China), PPD (Melbourne), CMAX (Adelaide) and CPR (Adelaide). |
Prof. Kate Seib is a principal research leader, associate director and acting deputy director at the Institute for Glycomics at Griffith University. Her expertise is in the field of molecular microbiology, with a focus on understanding virulence mechanisms and characterising vaccine antigens of human mucosal pathogens such as Neisseria gonorrhoeae and N. meningitidis. Her recent research includes the discovery and characterisation of gonococcal vaccine candidates, and health-impact modelling of gonococcal vaccines. She was involved in the development of the 4CMenB meningococcal vaccine and is currently leading clinical trials to evaluate the cross protection of 4CMenB against gonorrhoea. |
Prof. Helen Marshall AM is a consultant and professor in vaccinology at the Adelaide Medical School and the research director of the Women’s and Children’s Health Network. She is the director of the Vaccinology and Immunology Research Trials Unit, and is the leader of the Vaccines and Infectious Diseases Group in the Robinson Research Institute. She has previously been a member of ATAGI, and was awarded the South Australia Science Award (2019) and a Member of the Order of Australia (2022). She is a Fellow of the Academy of Health and Medical Sciences. She is the 2023 South Australian Scientist of the Year and South Australia’s 2022 Australian of the Year and Woman of the Year. |
Abstract
Neisseria gonorrhoeae infection presents a significant public health concern, with an increasing incidence and an escalating trend of antimicrobial resistance. The considerable morbidity of gonococcal infections primarily affects the reproductive and neonatal health of women and infants. This paper aims to consolidate the existing evidence concerning development and availability of N. gonorrhoeae vaccines and their potential to address the associated burden of disease. Furthermore, the review highlights the research gaps in discovery science and vaccine programs.
Keywords: cross protection, gonococcal infection, meningococcal vaccine, vaccine effectiveness.
Dr Bing Wang completed a PhD at The University of Adelaide in 2019. She received a MPhil degree in 2014 from The University of Adelaide and a bachelor’s degree in medicine from the Capital Medical University (Beijing, China). She has been working with her supervisor, Prof. Helen Marshall, on projects that require complex statistical analyses and have a health economic focus. She worked in the clinical research area for more than 10 years in GlaxoSmithKline (Beijing, China), PPD (Melbourne), CMAX (Adelaide) and CPR (Adelaide). |
Prof. Kate Seib is a principal research leader, associate director and acting deputy director at the Institute for Glycomics at Griffith University. Her expertise is in the field of molecular microbiology, with a focus on understanding virulence mechanisms and characterising vaccine antigens of human mucosal pathogens such as Neisseria gonorrhoeae and N. meningitidis. Her recent research includes the discovery and characterisation of gonococcal vaccine candidates, and health-impact modelling of gonococcal vaccines. She was involved in the development of the 4CMenB meningococcal vaccine and is currently leading clinical trials to evaluate the cross protection of 4CMenB against gonorrhoea. |
Prof. Helen Marshall AM is a consultant and professor in vaccinology at the Adelaide Medical School and the research director of the Women’s and Children’s Health Network. She is the director of the Vaccinology and Immunology Research Trials Unit, and is the leader of the Vaccines and Infectious Diseases Group in the Robinson Research Institute. She has previously been a member of ATAGI, and was awarded the South Australia Science Award (2019) and a Member of the Order of Australia (2022). She is a Fellow of the Academy of Health and Medical Sciences. She is the 2023 South Australian Scientist of the Year and South Australia’s 2022 Australian of the Year and Woman of the Year. |
References
1 World Health Organization (2021) Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016–2021: actions for impact. WHO, Geneva, Switzerland. https://www.who.int/publications/i/item/9789240027077
2 World Health Organization (2024) Implementing the global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, 2022–2030: report on progress and gaps 2024. WHO, Geneva, Switzerland. https://www.who.int/publications/i/item/9789240094925
3 Whelan J et al. (2021) Gonorrhoea: a systematic review of prevalence reporting globally. BMC Infect Dis 21(1), 1152.
| Crossref | Google Scholar | PubMed |
4 Naruka E, et al. (2023) Bloodborne viral and sexually transmissible infections in Aboriginal and Torres Strait Islander peoples: annual surveillance report 2023. Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. https://www.kirby.unsw.edu.au/research/reports/Blood-borne-viral-and-sexually-transmissible-infections-in-Aboriginal-and-Torres-Strait-Islander-peoples-Annual-surveillance-report-2023
5 Bautista CT et al. (2017) Repeat infection with Neisseria gonorrhoeae among active duty US Army personnel: a population-based case-series study. Int J STD AIDS 28(10), 962-968.
| Crossref | Google Scholar | PubMed |
6 Hosenfeld CB et al. (2009) Repeat infection with chlamydia and gonorrhea among females: a systematic review of the literature. Sex Transm Dis 36(8), 478-489.
| Crossref | Google Scholar | PubMed |
7 Williams E et al. (2024) Neisseria gonorrhoeae vaccines: a contemporary overview. Clin Microbiol Rev 37(1), e0009423.
| Crossref | Google Scholar | PubMed |
8 Vallely LM et al. (2021) Adverse pregnancy and neonatal outcomes associated with Neisseria gonorrhoeae: systematic review and meta-analysis. Sex Transm Infect 97(2), 104-111.
| Crossref | Google Scholar | PubMed |
9 Whelan J et al. (2021) Systematic literature review and quantitative analysis of health problems associated with sexually transmitted Neisseria gonorrhoeae infection. Infect Dis Ther 10(4), 1887-1905.
| Crossref | Google Scholar | PubMed |
10 Ward H, Rönn M (2010) Contribution of sexually transmitted infections to the sexual transmission of HIV. Curr Opin HIV AIDS 5(4), 305-310.
| Crossref | Google Scholar | PubMed |
11 King J, et al. (2023) HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2023. Kirby Institute, UNSW Sydney, Sydney, NSW, Australia. https://www.kirby.unsw.edu.au/research/reports/asr2023
12 Lyu Y et al. (2024) Vaccine value profile for Neisseria gonorrhoeae. Vaccine 42, S42-S69.
| Crossref | Google Scholar | PubMed |
13 Unemo M et al. (2017) Sexually transmitted infections: challenges ahead. Lancet Infect Dis 17(8), e235-e279.
| Crossref | Google Scholar | PubMed |
14 Bachmann LH et al. (2024) CDC clinical guidelines on the use of doxycycline postexposure prophylaxis for bacterial sexually transmitted infection prevention, United States, 2024. MMWR Recomm Rep 73(2), 1-8.
| Crossref | Google Scholar | PubMed |
15 Stewart J et al. (2023) Doxycycline prophylaxis to prevent sexually transmitted infections in women. N Engl J Med 389(25), 2331-2340.
| Crossref | Google Scholar | PubMed |
16 Molina JM et al. (2018) Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis 18(3), 308-317.
| Crossref | Google Scholar | PubMed |
17 Fifer H et al. (2016) Failure of dual antimicrobial therapy in treatment of gonorrhea. N Engl J Med 374(25), 2504-2506.
| Crossref | Google Scholar | PubMed |
18 Boslego JW et al. (1991) Efficacy trial of a parenteral gonococcal pilus vaccine in men. Vaccine 9(3), 154-162.
| Crossref | Google Scholar | PubMed |
19 Greenberg L et al. (1974) Gonococcal vaccine studies in Inuvik. Can J Public Health 65(1), 29-33.
| Google Scholar | PubMed |
20 Ruiz García Y et al. (2024) Urgent need to understand and prevent gonococcal infection: from the laboratory to real-world context. J Infect Dis jiae289.
| Crossref | Google Scholar | PubMed |
21 Piccioli D et al. (2022) GMMA as a ‘plug and play’ technology to tackle infectious disease to improve global health: context and perspectives for the future. Expert Rev Vaccines 21(2), 163-172.
| Crossref | Google Scholar | PubMed |
22 Reyes Díaz LM et al. (2021) VA-MENGOC-BC vaccination induces serum and mucosal anti-Neisseria gonorrhoeae immune responses and reduces the incidence of gonorrhea. Pediatr Infect Dis J 40(4), 375-381.
| Crossref | Google Scholar | PubMed |
23 Whelan J et al. (2016) Ecologic study of meningococcal B vaccine and Neisseria gonorrhoeae infection, Norway. Emerg Infect Dis 22(6), 1137-1139.
| Crossref | Google Scholar | PubMed |
24 Ruiz García Y et al. (2021) Looking beyond meningococcal B with the 4CMenB vaccine: the Neisseria effect. NPJ Vaccines 6(1), 130.
| Crossref | Google Scholar | PubMed |
25 Semchenko EA et al. (2019) The serogroup B meningococcal vaccine bexsero elicits antibodies to Neisseria gonorrhoeae. Clin Infect Dis 69(7), 1101-1111.
| Crossref | Google Scholar | PubMed |
26 Leduc I et al. (2020) The serogroup B meningococcal outer membrane vesicle-based vaccine 4CMenB induces cross-species protection against Neisseria gonorrhoeae. PLoS Pathog 16(12), e1008602.
| Crossref | Google Scholar | PubMed |
27 Abara WE et al. (2023) Healthy vaccinee bias and MenB-FHbp vaccine effectiveness against gonorrhea. Sex Transm Dis 50(6), e8-e10.
| Crossref | Google Scholar | PubMed |
28 Abara WE et al. (2022) Effectiveness of a serogroup B outer membrane vesicle meningococcal vaccine against gonorrhoea: a retrospective observational study. Lancet Infect Dis 22(7), 1021-1029.
| Crossref | Google Scholar | PubMed |
29 Bruxvoort KJ et al. (2023) Prevention of Neisseria gonorrhoeae with meningococcal B vaccine: a matched cohort study in southern California. Clin Infect Dis 76(3), e1341-e1349.
| Crossref | Google Scholar | PubMed |
30 Paynter J et al. (2019) Effectiveness of a group B outer membrane vesicle meningococcal vaccine in preventing hospitalization from gonorrhea in New Zealand: a retrospective cohort study. Vaccines 7(1), 5.
| Crossref | Google Scholar | PubMed |
31 Petousis-Harris H et al. (2017) Effectiveness of a group B outer membrane vesicle meningococcal vaccine against gonorrhoea in New Zealand: a retrospective case-control study. Lancet 390(10102), 1603-1610.
| Crossref | Google Scholar | PubMed |
32 Raccagni AR et al. (2023) Meningococcus B vaccination effectiveness against Neisseria gonorrhoeae infection in people living with HIV: a case–control study. Sex Transm Dis 50(5), 247-251.
| Crossref | Google Scholar | PubMed |
33 Robison SG, Leman RF (2023) Association of group B meningococcal vaccine receipt with reduced gonorrhea incidence among university students. JAMA Netw Open 6(8), e2331742.
| Crossref | Google Scholar | PubMed |
34 Wang B et al. (2023) 4CMenB sustained vaccine effectiveness against invasive meningococcal B disease and gonorrhoea at three years post programme implementation. J Infect 87(2), 95-102.
| Crossref | Google Scholar | PubMed |
35 Molina JM et al. (2024) Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2×2 factorial design. Lancet Infect Dis S1473-3099(24)00236-6.
| Crossref | Google Scholar | PubMed |
36 Longtin J et al. (2017) Possible impact of wide-scale vaccination against serogroup B Neisseria meningitidis on gonorrhea incidence rates in one region of Quebec, Canada. Open Forum Infect Dis 4(Supplement 1), S734-S735.
| Crossref | Google Scholar |
37 Nikitin D et al. (2024) Cost effectiveness of 4CMenB vaccination against gonorrhea: importance of dosing schedule, vaccine sentiment, targeting strategy, and duration of protection. J Infect Dis jiae123.
| Crossref | Google Scholar | PubMed |
38 Padeniya TN et al. (2024) Review of mathematical models of Neisseria gonorrhoeae vaccine impact: implications for vaccine development. Vaccine 42, S70-S81.
| Crossref | Google Scholar | PubMed |
39 Rowley J et al. (2019) Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ 97(8), 548-562.
| Crossref | Google Scholar | PubMed |
40 Hui BB et al. (2022) A gonococcal vaccine has the potential to rapidly reduce the incidence of Neisseria gonorrhoeae infection among urban men who have sex with men. J Infect Dis 225(6), 983-993.
| Crossref | Google Scholar | PubMed |
